Skip to content

    Sharda Cropchem

    SHARDACROP
    Chemicals·30 Jan 2026
    Management Summary

    Sharda Cropchem delivered a robust Q3 FY26 performance, driven by strong volume growth and an improved product mix, leading to a 39% YoY revenue increase and a 366% YoY PAT surge. The company achieved its highest-ever annual PAT in 9M FY26, supported by expanded gross and EBITDA margins. While Europe showed strong growth, the NAFTA region experienced a decline, and management acknowledged uncertainties in the product registration process and pricing recovery.

    Highlights

    6
    • Q3 FY26 revenue increased by 39% YoY to INR 1,289 crores.

    • PAT for Q3 FY26 surged by 366% YoY to INR 145 crores, marking the highest ever annual PAT achieved in 9M FY26.

    • EBITDA grew by 59% YoY to INR 245.5 crores, with EBITDA margin at 19.1%.

    • Gross margin expanded by 220 basis points to 34.9% in Q3 FY26 due to stabilizing input costs.

    • Working capital days improved significantly by 48 days to 70 days as of December 31, 2025.

    • The company remains net debt-free with INR 826 crores in cash and liquid investments.

    Concerns

    3
    • NAFTA region witnessed a decline year-on-year in Q3 FY26, attributed to 'heavy unpredictable and unusual climate conditions' without specific quantification.

    • Management highlighted significant uncertainties and variable timelines (1 to 7 years) in the product registration process, making it difficult to predict when the 1,070 pending registrations will become active and revenue-contributing.

    • Pricing levels are still 'quite down' compared to pre-COVID levels, though margins are improving due to lower sourcing costs.

    Key financials

    Metrics

    13

    Periods

    2

    Headline

    7
    • Revenue
      ₹1,289 Cr
      YoY+39%
    • EBITDA
      ₹245.5 Cr
      YoY+59%
    • EBITDA Margin
      19.1%
    • PAT
      ₹145.1 Cr
      YoY+3.7%
    • Gross Margin
      34.9%

    9M

    6
    • FY26 Revenue
      ₹3,203 Cr
      YoY+29.0%
    • FY26 EBITDA
      ₹526.7 Cr
      YoY+64%
    • FY26 EBITDA Margin
      16.4%
    • FY26 PAT
      ₹362 Cr
      YoY+2.6%
    • FY26 Gross Margin
      35%

    Segment breakdown

    • Agrochemical Business₹1,141 Cr88.5%
    • Non-Agrochemical Business₹148 Cr11.5%
    Donut· Share of Revenue (Q3 FY26)

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    ₹500 crores

    Debt

    Net ₹0 crores

    Dividend

    ₹6/share (interim)

    Liquidity

    Cash ₹826 crores

    Guidance & targets

    8
    CategoryTargetPriority
    Profitability
    EBITDA Margins
    18% to 20%
    High
    Profitability
    Gross Margin
    35% or higher
    High
    Volume
    Volume Growth
    15%
    High
    Capex
    Capital Expenditure
    INR 450-500 crores
    Medium
    Revenue
    Total Revenue Growth
    15% to 20%
    Medium
    Revenue
    Revenue Growth
    20%
    High
    Tax
    Tax Rate
    18% to 20%
    High
    Volume & Pricing
    Volume and Pricing Growth
    Same growth as expected for Q4
    High

    FY27 Volume Growth

    FY27
    Current14% overall volume growth in Q3 FY26
    Target15% volume growth for FY27

    Why it matters

    Volume growth is a key driver for revenue and indicates underlying demand strength.

    Hopefully, yes. We are very confident that 15% is achievable.

    How to verify

    key_financials.metrics[label='Revenue'].yoy_growth (in conjunction with realization)

    Risks & concerns

    4
    RiskSeverity

    Product Registration Uncertainties

    Registration process is full of uncertainties, with timelines varying from 1-2 years to 6-7 years, making it difficult to predict revenue contribution from 1,076 pending applications.Management acknowledged

    medium

    NAFTA Region Demand Decline

    NAFTA region experienced a year-on-year decline in Q3 FY26, attributed to 'heavy unpredictable and unusual climate conditions' without further explanation.Management acknowledged

    medium

    Pricing Levels Below Pre-COVID

    Current pricing levels are still 'quite down' compared to pre-COVID, though improved sourcing costs are leading to better margins.Management acknowledged

    low

    China Export Policy Opacity and Sourcing Constraints

    Management finds it difficult to comment on the impact of China's export rebate policy due to lack of transparency, and sourcing is tied to registered manufacturing plants, limiting diversification options.Analyst deflected

    medium

    Q&A highlights

    8

    “I have repeatedly mentioned in every conference that registration process is full of uncertainties, and nobody can predict how much time will it take. ... To give you an example, a registration may be obtained in 1 year or 2 years, and the same registration can take 6 to 7 years because of the uncertainties.”

    Highlights a key bottleneck and uncertainty in realizing revenue from the significant pipeline of 1,070 product registrations, impacting future growth visibility.

    asked by Ansh Shah

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Financial Performance Overview

    Sharda Cropchem reported a robust Q3 FY26, with total revenues growing by 39% year-on-year to INR 1,289 crores, driven by a 14% overall volume growth. The company achieved its highest-ever annual PAT in 9M FY26, with Q3 PAT surging by 366% YoY to INR 145 crores. EBITDA for the quarter increased by 59% to INR 245.5 crores, resulting in an EBITDA margin of 19.1%.

    02

    Segmental and Geographical Performance

    The Agrochemical business was a primary growth driver, expanding by 48% year-on-year to INR 1,141 crores in Q3 FY26. In contrast, the non-agrochemical business degrew by 8.1% to INR 148 crores. Geographically, Europe and Latin America showed strong volume growth, while the NAFTA region experienced a year-on-year decline, which management attributed to 'heavy unpredictable and unusual climate conditions'.

    03

    Margin Expansion and Cost Management

    Gross margins expanded by 220 basis points to 34.9% in Q3 FY26, and by 500 basis points to 35% for 9M FY26, primarily due to stabilizing input costs. Management noted that while current pricing levels are still lower than pre-COVID, improved sourcing costs have led to better overall margins for the company. They expect gross margins to be sustainable at 35% or higher for FY27.

    04

    Product Registration and Future Growth Pipeline

    The company continues to invest significantly in product registrations, holding 3,004 total registrations as of December 31, 2025, with an additional 1,076 applications globally in the approval stage. However, management emphasized the inherent uncertainties and variable timelines (1 to 7 years) in the registration process, making it difficult to predict when these will become active and contribute to revenues.

    05

    Capital Allocation and Shareholder Returns

    Sharda Cropchem remains a net debt-free company, holding INR 826 crores in cash and liquid investments as of December 31, 2025. The Board declared an interim dividend of INR 6 per share. For capital expenditure, INR 399 crores was spent in 9M FY26, with a planned INR 500 crores for FY26 and a guidance of INR 450-500 crores for FY27, indicating continued investment in growth.

    06

    Outlook and Guidance

    The company is confident in achieving a 15% volume growth for FY27 and expects total revenue growth of 15-20% for the same period. EBITDA margins are projected to be maintained in the 18-20% range for FY26. Management anticipates the growth momentum to continue into Q4 FY26 and remain strong through FY27, with Q4 historically being the strongest quarter.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.